4D MOLECULAR THERAPEUTICS IN (FDMT) Stock Income Statement
NASDAQ:FDMT - Nasdaq - US35104E1001 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 23.00K | 37.00K | 20.72M | 3.13M | 18.04M | |||
| Operating Expenses | 203.35M | 187.88M | 133.59M | 113.16M | 89.37M | |||
| Research and Development | 154.13M | 141.30M | 97.10M | 80.25M | 61.36M | |||
| Selling, General, and Administrative Expenses | 49.22M | 46.58M | 36.49M | 32.91M | 28.01M | |||
| Operating Income | -203.33M | -187.84M | -112.87M | -110.03M | -71.33M | |||
| Interest Income/Expense | 26.89M | 27.05M | 12.21M | 2.57M | 140.00K | |||
| Other Income/Expense | 0.00 | -77.00K | -181.00K | -40.00K | -120.00K | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -176.44M | -160.87M | -100.84M | -107.49M | -71.32M | |||
| Income Tax | N/A | 0.00 | N/A | N/A | N/A | |||
| Net Income | -176.44M | -160.87M | -100.84M | -107.49M | -71.32M | |||
| EBITDA | -196.04M | -181.14M | -107.12M | -107.63M | -69.81M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.17 | -2.98 | -2.58 | -3.32 | -2.57 | |||
| Non GAAP EPS | -3.18 | -2.98 | -2.64 | -3.32 | -2.56 | |||
| Statistics | ||||||||
| Profit Margin | -767126.09% | -434778.38% | -486.59% | -3434.19% | -395.34% | |||
| Operating Profit Margin | -884026.09% | -507678.38% | -544.65% | -3515.34% | -395.40% | |||
All data in USD